Group 1 - The core business of the company is the research, design, manufacturing, integration, and operation and maintenance services of medical gas equipment and systems, as well as medical clean equipment and systems [1] - The main customers served by the company are various medical institutions [1] - The company's medical gas equipment and systems, along with medical clean equipment and systems, are widely used in various medical institutions [1] Group 2 - The company plans to optimize its business layout based on actual operating conditions and development plans to better meet the needs of medical institutions [1]

Group 1 - The core viewpoint of the article is that 港通医疗 (Hongtong Medical) is focusing on the development of a smart hospital logistics management platform through its subsidiary, 港通智联数字科技 (Hongtong Zhilian Digital Technology) [1] - The company integrates big data, mobile internet technology, and IoT technology to enhance hospital logistics management [1] - The platform aims to upgrade hospital logistics management towards precision, professionalism, and efficiency through real-time data collection and deep analysis [1]

Core Viewpoint - The company, Hongtong Medical, reported that as of January 9, 2026, the total number of shareholders is 11,673 [2] Company Information - Hongtong Medical has a total of 11,673 shareholders as of the specified date [2]

Core Viewpoint - The company emphasizes the importance of its medical gas equipment and systems in ensuring a continuous supply of medical gases and maintaining cleanliness standards in operating rooms, thereby reducing the risk of postoperative infections [1]. Group 1 - The company's medical gas equipment and systems are designed to ensure the continuous supply of various medical gases [1]. - The medical clean equipment and systems provided by the company ensure that operating rooms and related areas meet cleanliness standards required for surgeries [1]. - The company highlights the necessity for specialized medical institutions to perform invasive brain-machine interface surgeries [1].

Group 1 - The core viewpoint of the article is that 港通医疗 emphasizes the importance of maintaining cleanliness standards in operating rooms for invasive brain-machine interface surgeries to reduce postoperative infection risks [1] - The company states that its medical gas equipment and systems ensure a continuous supply of medical gases, while its cleanroom equipment and systems help meet the cleanliness standards required for surgeries [1] - The company advises that invasive brain-machine interface surgeries should be performed by professional medical institutions and encourages investors to make rational investment decisions [1]

诺安多策略混合A（320016）基金经理为孔宪政。 截至发稿，孔宪政累计任职时间5年49天，现任基金资产总规模56.08亿元，任职期间最佳基金回报 93.39%， 任职期间最差基金回报-16.74%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月13日，港通医疗涨5.04%，截至发稿，报26.49元/股，成交1.54亿元，换手率9.51%，总市值26.49亿 元。 资料显示，四川港通医疗设备集团股份有限公司位于四川省成都市简阳市凯力威工业大道南段356号， 成立日期1998年1月13日，上市日期2023年7月25日，公司主营业务涉及为医疗机构提供以医用气体系统 及医院洁净手术部为核心的医疗专业工程整体方案。主营业务收入构成为：医用洁净装备及系统 55.69%，医用气体装备及系统37.30%，医疗设备及其他产品销售4.06%，运维服务2.81%，其他(补 充)0.14%。 从港通医疗十大流通股东角度 数据显示，诺安基金旗下1只基金位居港通医疗十大流通股东。诺安多策略 ...

Group 1 - The core viewpoint of the news is that Kangtong Medical has shown significant trading activity, with a notable increase in stock price and financing activities on January 12, indicating investor interest and market engagement [1] - On January 12, Kangtong Medical's stock price rose by 5.74%, with a trading volume of 286 million yuan, and a net financing purchase of 11.02 million yuan, reflecting strong market performance [1] - As of January 12, the total financing and securities lending balance for Kangtong Medical was 67.57 million yuan, which is 3.84% of its circulating market value, indicating a high level of financing activity compared to the past year [1] Group 2 - As of December 31, the number of shareholders for Kangtong Medical was 7,415, a decrease of 1.64% from the previous period, while the average circulating shares per person increased by 1.67% to 8,501 shares [2] - For the period from January to September 2025, Kangtong Medical reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a significant decline of 150.92% [2] - Since its A-share listing, Kangtong Medical has distributed a total of 48.99 million yuan in dividends [3]

创业板股最新融资余额为5721.72亿元，环比增加22.05亿元，39只股融资余额环比增长超10%，融资余 额环比降幅超10%的有15只。 证券时报·数据宝统计显示，1月9日创业板指上涨0.77%，创业板股两融余额合计5740.98亿元，较上一 交易日增加22.43亿元，已连续5个交易日增加。其中，融资余额合计5721.72亿元，环比上一日增加 22.05亿元；为连续5个交易日增加。融券余额19.25亿元，环比增加3788.63万元。 具体来看，融资余额增长的创业板股有478只，其中，39股融资余额增幅超过10%。增幅最大的是港通 医疗，该股最新融资余额5654.48万元，环比上一交易日增幅为59.20%；股价表现上，该股当日下跌 6.40%，表现弱于创业板指；融资余额增幅较多的还有邵阳液压、哈焊华通等，分别增长39.11%、 35.01%。 融资余额增幅10%以上的个股中，从市场表现来看，当日平均上涨5.43%，上涨的有31只，涨停的有泓 博医药、昆仑万维（维权）等2只，涨幅居前的有荣信文化、邵阳液压、国瓷材料，涨幅分别为 18.23%、17.84%、14.93%。跌幅居前的有荃银高科、三博脑科、港通医疗， ...

1月9日沪指上涨0.92%，市场两融余额为26276.01亿元，较前一交易日增加69.91亿元。 证券时报·数据宝统计显示，截至1月9日，沪市两融余额13212.13亿元，较前一交易日增加34.55亿元； 深市两融余额12979.40亿元，较前一交易日增加34.76亿元；北交所两融余额84.48亿元，较前一交易日 增加0.61亿元；深沪北两融余额合计26276.01亿元，较前一交易日增加69.91亿元。 融资余额降幅前20只个股 | 代码 | 简称 | 最新融资余额（万 | 较前一个交易日增减 | 当日涨跌幅（%） | 所属行业 | | --- | --- | --- | --- | --- | --- | | | | 元） | （%） | | | | 920564 | 天润科 技 | 965.15 | -56.71 | -5.25 | 计算机 | | 920641 | 格利尔 | 573.04 | -34.23 | 29.99 | 家用电器 | | 920158 | 长江能 科 | 443.10 | -31.56 | -0.12 | 机械设备 | | 603172 | 万丰股 份 | 3088.14 | - ...

Group 1 - The core point of the news is that 港通医疗 experienced a decline of 5.02% in its stock price, reaching 24.20 yuan per share, with a trading volume of 205 million yuan and a turnover rate of 13.05%, resulting in a total market capitalization of 2.42 billion yuan [1] - 港通医疗, established on January 13, 1998, and listed on July 25, 2023, specializes in providing medical gas systems and clean surgical room solutions to healthcare institutions [1] - The revenue composition of 港通医疗 includes: 55.69% from clean medical equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from sales of medical devices and other products, 2.81% from operation and maintenance services, and 0.14% from other sources [1] Group 2 - 诺安多策略混合A (320016) is among the top ten circulating shareholders of 港通医疗, holding 725,100 shares, which accounts for 1.15% of the circulating shares, with an estimated floating loss of approximately 928,100 yuan [2] - 诺安多策略混合A was established on August 9, 2011, with a latest scale of 1.855 billion yuan, achieving a year-to-date return of 2.79% and a one-year return of 80.52% [2] - The fund manager of 诺安多策略混合A is 孔宪政, who has been in the position for 5 years and 45 days, with the fund's total asset scale at 5.608 billion yuan, achieving a best return of 86.44% and a worst return of -16.74% during his tenure [3]